- Home
- IRS vs AUPH Comparison
IRS vs AUPH Comparison
Compare IRS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- AUPH
- Stock Information
- Founded
- IRS 1943
- AUPH 1993
- Country
- IRS Argentina
- AUPH Canada
- Employees
- IRS N/A
- AUPH N/A
- Industry
- IRS Homebuilding
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- IRS Real Estate
- AUPH Health Care
- Exchange
- IRS Nasdaq
- AUPH Nasdaq
- Market Cap
- IRS 1.1B
- AUPH 999.8M
- IPO Year
- IRS 1994
- AUPH 1999
- Fundamental
- Price
- IRS $14.38
- AUPH $8.18
- Analyst Decision
- IRS Strong Buy
- AUPH Strong Buy
- Analyst Count
- IRS 1
- AUPH 2
- Target Price
- IRS $12.62
- AUPH $11.50
- AVG Volume (30 Days)
- IRS 164.0K
- AUPH 1.3M
- Earning Date
- IRS 05-06-2025
- AUPH 05-05-2025
- Dividend Yield
- IRS 11.43%
- AUPH N/A
- EPS Growth
- IRS N/A
- AUPH N/A
- EPS
- IRS N/A
- AUPH 0.04
- Revenue
- IRS $325,094,048.00
- AUPH $235,133,000.00
- Revenue This Year
- IRS N/A
- AUPH $11.86
- Revenue Next Year
- IRS N/A
- AUPH $24.96
- P/E Ratio
- IRS N/A
- AUPH $204.50
- Revenue Growth
- IRS N/A
- AUPH 33.97
- 52 Week Low
- IRS $8.21
- AUPH $4.86
- 52 Week High
- IRS $17.67
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- IRS 58.48
- AUPH 56.33
- Support Level
- IRS $13.58
- AUPH $7.92
- Resistance Level
- IRS $14.68
- AUPH $8.32
- Average True Range (ATR)
- IRS 0.96
- AUPH 0.34
- MACD
- IRS 0.19
- AUPH 0.07
- Stochastic Oscillator
- IRS 89.98
- AUPH 90.64
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.